Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy

  • Orphan Drug Designation received from European Medicines Agency for Estetrol (E4) in the treatment of life-threatening Neonatal Encephalopathy
  • Evidence of potential of E4 to address additional indications beyond Women’s Health
  • Preclinical results form basis for potential additional partnerships for E4
Liège, Belgium 9 June 2017 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has received Orphan Drug Designation (ODD) for E4 in Neonatal Encephalopathy (NE). Mithra intends to develop E4 to treat Hypoxic Ischemic Encephalopathy (HIE), a subset of NE which accounts for 50-80% of cases and affects pre-term and new born babies (>36 weeks gestation).